{"title":"Lucius Pharmaceuticals","description":null,"products":[{"product_id":"generic-afatinib-luciafa","title":"LuciAfa (Afatinib)","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS AND USAGE\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eAfatinib is a kinase inhibitor indicated for:\u003c\/p\u003e\u003cp\u003e• First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.\u003c\/p\u003e\u003cp\u003eLimitations of Use: Safety and efficacy of LuciAfa were not established in patients whose tumors have resistant EGFR mutations .\u003c\/p\u003e\u003cp\u003e• Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy .\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eDOSAGE AND ADMINISTRATION\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003e• Recommended dosage: 40 mg orally once daily.\u003c\/p\u003e\u003cp\u003e• Renal impairment: 30 mg orally once daily in patients with severe renal impairment.\u003c\/p\u003e\u003cp\u003e• Instruct patients to take LuciAfa at least 1 hour before or 2 hours after a meal.\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797953998891,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0834.jpg?v=1787022212"},{"product_id":"generic-erlotinib-lucierlo","title":"LuciErlo (Erlotinib)","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS AND USAGE\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eErlotinib is a kinase inhibitor indicated for:\u003c\/p\u003e\u003cp\u003e· The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.\u003c\/p\u003e\u003cp\u003e· First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.\u003c\/p\u003e\u003cp\u003eLimitations of Use:\u003c\/p\u003e\u003cp\u003e· Safety and efficacy of LuciErlo have not been established in patients with NSCLC whose tumors have other EGFR mutations.\u003c\/p\u003e\u003cp\u003e· LuciErlo is not recommended for use in combination with platinumbased chemotherapy.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eDOSAGE AND ADMINISTRATION\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003e· NSCLC: 150 mg orally, on an empty stomach, once daily.\u003c\/p\u003e\u003cp\u003e· Pancreatic cancer: 100 mg orally, on an empty stomach, once daily.\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954031659,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0843.jpg?v=1787022214"},{"product_id":"generic-dacomitinib-lucidac","title":"LuciDac (Dacomitinib)","description":"\u003cp\u003e\u003cstrong\u003eINDICATIONS AND USAGE\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eDacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eDOSAGE AND ADMINISTRATION\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eRecommended Dosage: 45 mg orally once daily with or without food.\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954064427,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-086.jpg?v=1787022215"},{"product_id":"lcuipirto-pirtobrutinib","title":"LcuiPirto (Pirtobrutinib)","description":"\u003ch2\u003eAbout Pirtobrutinib \u003c\/h2\u003e\u003cp\u003ePirtobrutinib is an inhibits B cell lymphocyte proliferation and survival by binding and inhibiting Bruton's tyrosine kinase (BTK).\u003csup id=\"cite_ref-Aslan_2022_5-0\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch2\u003eMantle Cell Lymphoma\u003c\/h2\u003e\u003cp\u003eIndicated for relapsed or refractory mantle cell lymphoma (MCL) after at least 2 lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor\u003c\/p\u003e\u003cp\u003e200 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eChronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma\u003c\/h2\u003e\u003cp\u003eIndicated for chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) in adults who have received at ≥2 prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor\u003c\/p\u003e\u003cp\u003e200 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch2\u003eDosage Modifications\u003c\/h2\u003e\u003cp\u003eAsymptomatic lymphocytosis: Dose modification not recommended\u003c\/p\u003e\u003cp\u003eAsymptomatic lipase increase: May not necessarily warrant a dose modification\u003c\/p\u003e\u003ch2\u003eHematologic toxicities\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eNOTE: Based on starting dose of 200 mg qDay\u003c\/li\u003e\n\u003cli\u003eAbsolute neutrophil count (ANC) 0.5 to \u0026lt;1 x 10\u003csup\u003e9\u003c\/sup\u003e\/L with fever and\/or infection\u003c\/li\u003e\n\u003cli\u003eANC \u0026lt;0.5 x 10\u003csup\u003e9\u003c\/sup\u003e\/L lasting ≥7 days\u003c\/li\u003e\n\u003cli\u003ePlatelet count 25 to \u0026lt;50 x 10\u003csup\u003e9\u003c\/sup\u003e\/L with bleeding\u003c\/li\u003e\n\u003cli\u003ePlatelet count \u0026lt;25 x 10\u003csup\u003e9\u003c\/sup\u003e\/L\u003c\/li\u003e\n\u003cli\u003e\n\u003ch3\u003eModification\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003eFirst occurrence: Interrupt therapy until recovery to Grade 1 or baseline; restart at original dose (200 mg qDay)\u003c\/li\u003e\n\u003cli\u003eSecond occurrence: Interrupt therapy until recovery to Grade 1 or baseline; restart at 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eThird occurrence: Interrupt therapy until recovery to Grade 1 or baseline; restart at 50 mg qDay\u003c\/li\u003e\n\u003cli\u003eFourth occurrence: Discontinue treatment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954162731,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0871.jpg?v=1787022218"},{"product_id":"lucianagre-anagrelide","title":"LuciAnagre (Anagrelide)","description":"\u003ch2\u003eAbout Anagrelide\u003c\/h2\u003e\u003cp\u003eAnagrelide is a drug used for the treatment of essential thrombocytosis (also known as essential thrombocythemia), or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia.\u003c\/p\u003e\u003ch3\u003eThrombocythemia\u003c\/h3\u003e\u003cp\u003eIndicated for essential thrombocythemia and for thrombocythemia secondary to myeloproliferative disorders to decrease risk thrombosis and thrombo-hemorrhagic event\u003c\/p\u003e\u003cp\u003e0.5 PO q6hr or 1 mg q12hr; increase PRN not more frequently than 0.5 mg\/day\/week\u003c\/p\u003e\u003cp\u003eNot to exceed 10 mg\/day or 2.5 mg\/dose\u003c\/p\u003e\u003cp\u003ePlatelet count responds typically in 7-14 days; time to complete response is 4 to 12 weeks\u003c\/p\u003e\u003ch3\u003ePolycythemia Vera (Orphan)\u003c\/h3\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954195499,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0859.jpg?v=1787022220"},{"product_id":"lucitivo-tivozanib","title":"LuciTivo (Tivozanib)","description":"\u003ch2\u003eAbout Tivozanib\u003c\/h2\u003e\u003cp\u003eTivozanib  is a medication used for the treatment of advanced renal cell carcinoma (kidney cancer).\u003csup id=\"cite_ref-FDA_tivozanib_3-1\" class=\"reference\"\u003e\u003c\/sup\u003eIt is an oral VEGF receptor tyrosine kinase inhibitor.\u003c\/p\u003e\u003ch3\u003eRenal Cell Carcinoma\u003c\/h3\u003e\u003cp\u003eIndicated for relapsed or refractory advanced renal cell carcinoma in patients previously treated with ≥2 systemic therapies\u003c\/p\u003e\u003cp\u003e1.34 mg PO qDay on Days 1-21 of repeated 28-day cycles\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003eIf dose modifications are required for adverse reactions, reduce to 0.89 mg qDay for 21 days followed by 7 days off treatment\u003c\/p\u003e\u003cp\u003eInitiate medical management for diarrhea, nausea, or vomiting prior to dose interruption or reduction\u003c\/p\u003e\u003ch4\u003eHypertension\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold for persistent Grade 3 despite optimal antihypertensive therapy\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose when hypertension controlled at Grade ≤2\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCardiac failure\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until improves to Grade ≤1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose or discontinue depending on severity and persistence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eArterial thromboembolic events or reverse posterior leukoencephalopathy syndrome (RPLS)\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eAny grade: Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eHemorrhagic events\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 3 or 4: Permanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eProteinuria\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003e2 grams or greater proteinuria in 24 hr\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until less than or equal to 2 grams of proteinuria per 24 hr\u003c\/li\u003e\n\u003cli\u003eResume at a reduced dose\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue for nephrotic syndrome\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003ePersistent or intolerable Grade 2 or 3 OR Grade 4 laboratory abnormality\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eWithhold until improves to Grade ≤1 or baseline; resume at reduced dose\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-severe (CrCl 15-89 mL\/min): No dosage modifications\u003c\/li\u003e\n\u003cli\u003eEnd-stage renal disease: Recommend dose not established\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (total bilirubin [TB] ≤1.5x ULN with any AST): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate (TB \u0026gt;1.5 to 3x ULN with any AST): Reduce to 0.89 mg qDay\u003c\/li\u003e\n\u003cli\u003eSevere (TB 3 to 10x ULN with any AST): Not established\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eVerify pregnancy in females of reproductive potential before initiation\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954293803,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0821.jpg?v=1787022221"},{"product_id":"luciasc-asciminib","title":"LuciAsc (Asciminib)","description":"\u003ch2\u003eAbout Asciminib\u003c\/h2\u003e\u003cp\u003eAsciminib is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).\u003csup id=\"cite_ref-Scemblix_FDA_label_5-1\" class=\"reference\"\u003e\u003c\/sup\u003e Asciminib is a protein kinase inhibitor.\u003csup id=\"cite_ref-Scemblix_FDA_label_5-2\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003eChronic Myeloid Leukemia\u003c\/h3\u003e\u003ch4\u003eNewly diagnosed\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)\u003c\/li\u003e\n\u003cli\u003e80 mg PO daily OR 40 mg PO BID\u003c\/li\u003e\n\u003cli\u003eContinue for as long as clinical benefit is observed or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003ePreviously treated\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in adults with previously treated Ph+ CML in CP\u003c\/li\u003e\n\u003cli\u003e80 mg PO daily OR 40 mg PO BID\u003c\/li\u003e\n\u003cli\u003eContinue for as long as clinical benefit is observed or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eWith T315I mutation\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in adults with Ph+ CML in CP with T315I mutation\u003c\/li\u003e\n\u003cli\u003e200 mg PO BID\u003c\/li\u003e\n\u003cli\u003eContinue for as long as clinical benefit is observed or until unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954326571,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0813.jpg?v=1787022223"},{"product_id":"luciquiza-quizartinib","title":"LuciQuiza (Quizartinib)","description":"\u003ch2\u003eAbout Quizartinib\u003c\/h2\u003e\u003cp\u003eQuizartinib is an anti-cancer medication used for the treatment of acute myeloid leukemia. It is a small molecule receptor tyrosine kinase inhibitor. Its molecular target is FLT3, also known as CD135 which is a proto-oncogene.FLT3 mutations are among the most common mutations in acute myeloid leukemia due to internal tandem duplication of FLT3, and the presence of this mutation is a marker of adverse outcome.\u003c\/p\u003e\u003ch3\u003eAcute Myeloid Leukemia\u003c\/h3\u003e\u003cp\u003eIndicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test\u003c\/p\u003e\u003cp\u003eEach cycle is 28 days\u003c\/p\u003e\u003cp\u003eIf patient proceeds to hematopoietic stem cell transplantation (HSCT), stop quizartinib 7 days before starting conditioning regimen\u003c\/p\u003e\u003ch4\u003eInduction\u003c\/h4\u003e\u003cp\u003eMay receive up to 2 cycles of induction\u003c\/p\u003e\u003cp\u003eQuizartinib 35.4 mg PO qDay on Days 8-21, PLUS\u003c\/p\u003e\u003cp\u003e7 + 3 regimen (cytarabine 100 or 200 mg\/m\u003csup\u003e2\u003c\/sup\u003e\/day IV on Days 1-7 plus daunorubicin 60 mg\/m\u003csup\u003e2\u003c\/sup\u003e\/day IV or idarubicin 12 mg\/m\u003csup\u003e2\u003c\/sup\u003e\/day IV on Days 1-3)\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003ch5\u003eOptional second induction\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eQuizartinib plus 7 + 3 or 5 + 2 regimen (5 days cytarabine plus 2 days daunorubicin or idarubicin)\u003c\/li\u003e\n\u003cli\u003eIf 5 + 2 regimen administered as second induction cycle, administer quizartinib on Days 6-19\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eConsolidation\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eQuizartinib 35.4 mg PO qDay on Days 6-19, PLUS\u003c\/li\u003e\n\u003cli\u003eCytarabine 1.5-3 g\/m2 q12hr on Days 1, 3, and 5 for up to 4 cycles\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eMaintenance\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eQuizartinib 26.5 mg PO qDay on Days 1-14 of the first cycle if QTcF ≤450 ms\u003c\/li\u003e\n\u003cli\u003eIncrease dose to 53 mg once daily on Day 15 of first cycle if QTcF ≤450 ms\u003c\/li\u003e\n\u003cli\u003eMaintain 26.5 mg PO qDay if QTcF \u0026gt;500 ms was observed during induction or consolidation\u003c\/li\u003e\n\u003cli\u003eDuration is once daily with no break between cycles for up to 36 cycles\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954654251,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-089.jpg?v=1787022224"},{"product_id":"lucipona-ponatinib","title":"LuciPona (Ponatinib)","description":"\u003ch2\u003eAbout Ponatinib \u003c\/h2\u003e\u003cp\u003ePonatinib is a medication used for the treatment of chronic myeloid leukemia and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia.  It is a multi-targeted tyrosine-kinase inhibitor.\u003csup id=\"cite_ref-pmid20513156_5-0\" class=\"reference\"\u003e\u003c\/sup\u003e Some forms of chronic myeloid leukemia, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.\u003c\/p\u003e\u003ch3\u003eChronic Myeloid Leukemia\u003c\/h3\u003e\u003ch4\u003eChronic phase (CP) chronic myeloid leukemia (CML)\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for patients with CP-CML with resistance or intolerance to at least 2 prior kinase inhibitors\u003c\/li\u003e\n\u003cli\u003e45 mg PO qDay initially\u003c\/li\u003e\n\u003cli\u003eReduce to 15 mg PO qDay upon achievement of ≤1% BCR-ABL1IS\u003c\/li\u003e\n\u003cli\u003eRe-escalate dose to previously tolerated dosage of 30 mg or 45 mg PO qDay in patients with loss of response\u003c\/li\u003e\n\u003cli\u003eContinue until loss of response at the re-escalated dose or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eConsider discontinuing treatment if response has not occurred by 3 months\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eAccelerated phase (AP) or blast phase (BP) CML\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for AP-CML or BP-CML for whom no other kinase inhibitors are indicated, and for T315I-postive CML (CP, AP, BP)\u003c\/li\u003e\n\u003cli\u003eOptimal dose not identified\u003c\/li\u003e\n\u003cli\u003e45 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eConsider reducing dose for AP-CML in patients who have achieved a major cytogenetic response\u003c\/li\u003e\n\u003cli\u003eContinue until loss of response or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eConsider discontinuing treatment if response has not occurred by 3 months\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003ePhiladelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)\u003c\/h3\u003e\u003ch4\u003eNewly diagnosed in combination with chemotherapy\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndication for Ph+ ALL based on minimal residual disease (MRD)-negative complete remission (CR) at end of induction\u003c\/li\u003e\n\u003cli\u003e30 mg PO qDay; reduce to 15 mg PO qDay upon achievement of MRD-negative (≤0.01% BCR::ABL1\/ABL1) CR at end of induction\u003c\/li\u003e\n\u003cli\u003eContinue in combination with chemotherapy for up to 20 cycles (each cycle is 28 days) until loss of response or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eInduction (cycles 1-3)\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003ePonatinib 30 mg PO qDay, plus\u003c\/li\u003e\n\u003cli\u003eVincristine 1.4 mg\/m\u003csup\u003e2\u003c\/sup\u003e IV on Days 1 and 14 (not to exceed 2 mg\/dose), a\u003cb\u003end\u003c\/b\u003e\n\u003c\/li\u003e\n\u003cli\u003eDexamethasone: 40 mg (age \u0026lt;60 yr) or 20 mg (age ≥60 yr) PO on Days 1-4 and Days 11-14\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eConsolidation (cycles 4-9, alternating methotrexate and cytarabine)\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003ePonatinib 30 mg (or decreased to 15 mg if in MRD-negative CR) PO qDay, plus\u003c\/li\u003e\n\u003cli\u003eMethotrexate (cycles 4, 6, and 8): 1000 mg\/m\u003csup\u003e2\u003c\/sup\u003e (age \u0026lt;60 yr) or 250 mg\/m\u003csup\u003e2\u003c\/sup\u003e (age ≥60 yr) IV on Day 1, OR\u003c\/li\u003e\n\u003cli\u003eCytarabine (cycles 5, 7, and 9): 1000 mg\/m\u003csup\u003e2\u003c\/sup\u003e (age \u0026lt;60 yr) or 250 mg\/m\u003csup\u003e2\u003c\/sup\u003e (age ≥60 yr) IV q12hr on Days 1, 3, and 5\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eMaintenance (cycles 10-20)\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003ePonatinib 30 mg (or decreased to 15 mg if in MRD-negative CR) PO qDay, plus\u003c\/li\u003e\n\u003cli\u003eVincristine 1.4 mg\/m\u003csup\u003e2\u003c\/sup\u003e IV on Day 1 (not to exceed 2 mg\/dose), and\u003c\/li\u003e\n\u003cli\u003ePrednisone: 200 mg (aged \u0026lt;60 yr) or 100 mg (age ≥60 to 69 yr) or 50 mg (age ≥70 yr) PO on Days 1-5\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eMonotherapy\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for patients with Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-postive Ph+ ALL\u003c\/li\u003e\n\u003cli\u003eOptimal dose not identified\u003c\/li\u003e\n\u003cli\u003e45 mg PO qDay initially\u003c\/li\u003e\n\u003cli\u003eContinue until loss of response or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eConsider discontinuing treatment if response has not occurred by 3 months\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954719787,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0866.jpg?v=1787022225"},{"product_id":"lucisuni-sunitinib","title":"LuciSuni (Sunitinib)","description":"\u003ch2\u003eAbout Sunitinib\u003c\/h2\u003e\u003cp\u003eSunitinib is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications.\u003csup id=\"cite_ref-FDA_3-0\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003eGastrointestinal Stromal Tumor\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate\u003c\/p\u003e\u003cp\u003e50 mg PO qDay for 4 weeks, THEN 2 weeks drug-free, repeat cycle\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eRenal Cell Carcinoma\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of advanced renal cell carcinoma (RCC)\u003c\/p\u003e\u003cp\u003e50 mg PO qDay for 4 weeks, THEN 2 weeks drug-free, repeat cycle\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch4\u003eAdjuvant treatment of RCC\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy\u003c\/li\u003e\n\u003cli\u003e50 mg PO qDay for 4 weeks, THEN 2 weeks drug-free, repeat cycle for a total of nine 6-week cycles\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003ePancreatic Neuroendocrine Tumors\u003c\/h3\u003e\u003cp\u003eIndicated for progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease\u003c\/p\u003e\u003cp\u003e37.5 mg PO qDay continuously without a scheduled off-treatment period\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954752555,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0922.jpg?v=1787022227"},{"product_id":"luciaxi-axitinib","title":"LuciAxi (Axitinib)","description":"\u003ch2\u003eAbout Axitinib\u003c\/h2\u003e\u003cp\u003eAxitinib  is a small molecule tyrosine kinase inhibitor. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models\u003csup id=\"cite_ref-4\" class=\"reference\"\u003e\u003c\/sup\u003e and has shown partial responses in clinical trials with renal cell carcinoma (RCC)\u003cspan style=\"font-size: 13.3333px\"\u003e  \u003c\/span\u003eand several other tumour types.\u003csup id=\"cite_ref-6\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003eRenal Cell Carcinoma\u003c\/h3\u003e\u003ch4\u003eMonotherapy\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for advanced renal cell carcinoma (RCC) in patients who failed 1 prior systemic therapy\u003c\/li\u003e\n\u003cli\u003e5 mg PO BID initially\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCombination therapy with avelumab\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with avelumab for first-line treatment of advanced RCC\u003c\/li\u003e\n\u003cli\u003eAxitinib 5 mg PO BID, plus\u003c\/li\u003e\n\u003cli\u003eAvelumab 800 mg IV q2Weeks\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eDuring combination therapy with avelumab, consider escalating dose of axitinib above 5 mg\/dose in 2-week intervals or longer\u003c\/li\u003e\n\u003cli\u003eRefer the prescribing information of avelumab for dosing information\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCombination therapy with pembrolizumab\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with pembrolizumab for first-line treatment of advanced RCC\u003c\/li\u003e\n\u003cli\u003eAxitinib 5 mg PO BID, plus\u003c\/li\u003e\n\u003cli\u003ePembrolizumab 200 mg IV q3Weeks or 400 mg IV q6Weeks\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eDuring combination therapy with pembrolizumab, consider escalating dose of axitinib above 5 mg\/dose in 6-week intervals or longer\u003c\/li\u003e\n\u003cli\u003eRefer the prescribing information of pembrolizumab for dosing information\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954785323,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0927.jpg?v=1787022228"},{"product_id":"lucivemu-vemurafenib","title":"LuciVemu (Vemurafenib)","description":"\u003ch2\u003eAbout Vemurafenib \u003c\/h2\u003e\u003cp\u003eVemurafenib is a medication used for the treatment of late-stage melanoma.\u003csup id=\"cite_ref-pmid20823850_2-1\" class=\"reference\"\u003e\u003c\/sup\u003e It is an inhibitor of the B-Raf enzyme.\u003c\/p\u003e\u003cdiv class=\"drugdbsectioncontent drug\"\u003e\u003cdiv id=\"content_0\"\u003e\u003cdiv class=\"refsection_content\"\u003e\u003cdiv id=\"dose_tabs_content\"\u003e\u003cdiv id=\"dose_adult\"\u003e\n\u003ch3\u003eMalignant Melanoma\u003c\/h3\u003e\n\u003cp\u003eIndicated for treatment of unresectable or metastatic melanoma with BRAF-V600E mutation as detected by an FDA-approved test\u003c\/p\u003e\n\u003cp\u003e960 mg (4 x 240 mg tablets) PO q12hr (administer approximately 12 hr apart)\u003c\/p\u003e\n\u003cp\u003eSee also Administration\u003c\/p\u003e\n\u003ch3\u003eErdheim-Chester Disease\u003c\/h3\u003e\n\u003cp\u003eIndicated for the treatment of Erdheim-Chester Disease (ECD) with BRAF V600 mutation\u003c\/p\u003e\n\u003cp\u003e960 mg (4 x 240 mg tablets) PO q12hr (administer approximately 12 hr apart)\u003c\/p\u003e\n\u003ch3\u003eOrphan Designations\u003c\/h3\u003e\n\u003cp\u003eThyroid cancer: Treatment of anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a BRAF V600 mutation\u003c\/p\u003e\n\u003cp\u003eNon-small cell lung cancer (NSCLC) with BRAF V600E mutation\u003c\/p\u003e\n\u003c\/div\u003e\u003c\/div\u003e\u003c\/div\u003e\u003c\/div\u003e\u003c\/div\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954818091,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0946.jpg?v=1787022229"},{"product_id":"luciribo-ribociclib","title":"LuciRibo (Ribociclib)","description":"\u003ch2\u003eAbout Ribociclib\u003c\/h2\u003e\u003cp\u003eRibociclib is a targets proteins called cyclin dependant kinase 4 and cyclin dependant 6 (CDK 4 and CDK 6) on breast cancer cells. CDK 4 and CDK 6 are proteins that stimulate cancer cells to divide and grow. Ribociclib works by blocking these proteins.\u003c\/p\u003e\u003ch3\u003eBreast Cancer\u003c\/h3\u003e\u003ch4\u003eEarly breast cancer\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with an aromatase inhibitor for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence\u003c\/li\u003e\n\u003cli\u003e400 mg PO daily for 21 consecutive days followed by 7 days off treatment\u003c\/li\u003e\n\u003cli\u003eRepeat in 28-day cycles for 3 years or until disease recurrence or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eRefer to prescribing information for the recommended dose of the aromatase inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eAdvanced or metastatic breast cancer\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for HR-positive, HER2-negative advanced or metastatic breast cancer\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eIn combination with an aromatase inhibitor as initial endocrine-based therapy\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e600 mg PO daily for 21 consecutive days followed by 7 days off treatment\u003c\/li\u003e\n\u003cli\u003eRepeat in 28-day cycles until disease recurrence or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eRefer to prescribing information for the recommended dose of the aromatase inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eIn combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e600 mg PO daily for 21 consecutive days followed by 7 days off treatment; repeat in 28-day cycles until disease recurrence or unacceptable toxicity, \u003cstrong\u003ePLUS\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFulvestrant 500 mg IM on Days 1,15, and 29, followed by 500 mg IM monthly thereafter\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003eReview the prescribing information for the coadministered aromatase inhibitor or fulvestrant for dosage modifications\u003c\/p\u003e\u003ch4\u003eRecommended dose modifications for adverse effects\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eEarly breast cancer\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eStarting dose: 400 mg\/day\u003c\/li\u003e\n\u003cli\u003eDose reduction: 200 mg\/day; discontinue if further dose adjustment is required\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eAdvanced or metastatic breast cancer\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eStarting dose: 600 mg\/day\u003c\/li\u003e\n\u003cli\u003eFirst dose reduction: 400 mg\/day\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 200 mg\/day; discontinue if further dose adjustment is required\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954883627,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0937.jpg?v=1787022230"},{"product_id":"lucialpe-alpelisib","title":"LuciAlpe (Alpelisib)","description":"\u003ch2\u003eAbout Alpelisib\u003c\/h2\u003e\u003cp\u003eAlpelisib is a medication used to treat certain types of breast cancer.\u003csup id=\"cite_ref-FDA2019_8-0\" class=\"reference\"\u003e\u003c\/sup\u003e It is used together with fulvestrant.\u003csup id=\"cite_ref-FDA2019_8-1\" class=\"reference\"\u003e\u003c\/sup\u003e\u003csup id=\"cite_ref-FDA2019_8-4\" class=\"reference\"\u003e\u003c\/sup\u003e It is an alpha-specific PI3K inhibitor.\u003csup id=\"cite_ref-FDA2019_8-5\" class=\"reference\"\u003e\u003c\/sup\u003e \u003c\/p\u003e\u003ch3\u003eBreast Cancer\u003c\/h3\u003e\u003cp\u003eKinase inhibitor indicated in combination with fulvestrant for treatment of men and pre-, peri-, or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen\u003c\/p\u003e\u003cp\u003eAlpelisib 300 mg PO qDay AND\u003c\/p\u003e\u003cp\u003eFulvestrant 500 mg IM on Days 1, 15, and 29, and once monthly thereafter\u003c\/p\u003e\u003cp\u003eContinue treatment until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003cp\u003eRefer to the full prescribing information for fulvestrant\u003c\/p\u003e\u003ch3\u003ePIK3CA-Related Overgrowth Spectrum\u003c\/h3\u003e\u003cp\u003eVijoice onlyIndicated for severe manifestations of PIK3CA-related overgrowth spectrum (PROS) in patients who require systemic therapy\u003c\/p\u003e\u003cp\u003e250 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955407915,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0974.jpg?v=1787022231"},{"product_id":"luciviga-vigabatrin","title":"LuciViga (Vigabatrin)","description":"\u003ch2\u003eAbout Vigabatrin\u003c\/h2\u003e\u003cp\u003eVigabatrin is used alone or together with other medicines to treat refractory complex partial seizures in adults and children 2 years of age and older, and infantile spasms in children. It is used in patients who have already been treated with other medicines that did not work well. Vigabatrin is an anticonvulsant.\u003c\/p\u003e\u003ch3\u003ePartial Seizures\u003c\/h3\u003e\u003cp\u003eIndicated as adjunctive therapy for refractory complex partial seizures in patients who have inadequately responded to several seizure treatments and for whom the potential benefits of vigabatrin outweigh the risk of vision loss\u003c\/p\u003e\u003cp\u003e500 mg PO q12hr initially, THEN increase by 500-mg increments qWeek to target dose of 1.5 g q12hr\u003c\/p\u003e\u003cp\u003eNo additional benefit shown with 6 g daily compared with 3 g daily; higher incidence of adverse effects associated with 6 g daily\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (CrCl \u0026gt;50 to 80 mL\/min): Decrease dose by 25%\u003c\/li\u003e\n\u003cli\u003eModerate (CrCl \u0026gt;30 to 50 mL\/min): Decrease dose by 50%\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026gt;10 to 30 mL\/min): Decrease dose by 75%\u003c\/li\u003e\n\u003cli\u003eHemodialysis: Clearance not adequately studied\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955440683,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-093.jpg?v=1787022232"},{"product_id":"lucianam-anamorelin","title":"LuciAnam (Anamorelin)","description":"\u003ch2\u003eAbout Anamorelin\u003c\/h2\u003e\u003cp\u003eAnamorelin (developmental code names ONO-7643, RC-1291, ST-1291), also known as anamorelin hydrochloride (USAN, JAN), is a non-peptide, orally-active, centrally-penetrant, selective agonist of the ghrelin\/growth hormone secretagogue receptor (GHSR) with appetite-enhancing and anabolic effects which is development for the treatment of cancer cachexia and anorexia.\u003c\/p\u003e\u003cp\u003eAnamorelin significantly increases plasma levels of growth hormone (GH), insulin-like growth factor 1 (IGF-1), and insulin-like growth factor-binding protein 3 (IGFBP-3) in humans, without affecting plasma levels of prolactin, cortisol, insulin, glucose, adrenocorticotropic hormone (ACTH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), or thyroid-stimulating hormone (TSH).\u003csup id=\"cite_ref-GarciaPolvino2009_3-1\" class=\"reference\"\u003e\u003c\/sup\u003e In addition, anamorelin significantly increases appetite, overall body weight, lean body mass, and muscle strength,\u003csup id=\"cite_ref-GarciaBoccia2015_4-1\" class=\"reference\"\u003e\u003c\/sup\u003ewith increases in body weight correlating directly with increases in plasma IGF-1 levels.\u003csup id=\"cite_ref-GarciaPolvino2009_3-2\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003eIndication\u003c\/h3\u003e\u003cp\u003eCancer cachexia in the following malignant tumors:\u003cbr\u003eNon-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer\u003c\/p\u003e\u003ch3\u003eDosage and administration\u003c\/h3\u003e\u003cp\u003eUsually, for adults, administer 100 mg of anamorelin hydrochloride at fasting state orally once a day.\u003c\/p\u003e\u003cp\u003eDo not eat within 1 hour after taking this medicine. If you do not notice weight gain or improvement in appetite, in principle, you should stop taking it 3 weeks after starting.\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955506219,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1043.jpg?v=1787022234"},{"product_id":"lucielace-elacestrant","title":"LuciElace (Elacestrant)","description":"\u003ch2\u003eAbout Elacestrant\u003c\/h2\u003e\u003cp\u003eAbout Elacestrant  is a selective estrogen receptor degrader (SERD) used in the treatment of breast cancer. Elacestrant is an antiestrogen that acts as an antagonist of estrogen receptors, which are the biological targets of endogenous estrogens like estradiol. \u003c\/p\u003e\u003cp\u003eElacestrant is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one other line of endocrine therapy.\u003c\/p\u003e\u003ch3\u003eBreast Cancer\u003c\/h3\u003e\u003cp\u003eIndicated for men or postmenopausal women with estrogen receptor positive (ER+), HER\u003csub\u003e2\u003c\/sub\u003e-negative, ESR\u003csub\u003e1\u003c\/sub\u003e-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy\u003c\/p\u003e\u003cp\u003e345 mg PO qDay with food until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDose reduction recommendations for adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 258 mg qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 172 mg qDay\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if dose reduction \u0026lt;172 mg\/day required\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eModifications for adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 1: Continue at current dose level\u003c\/li\u003e\n\u003cli\u003eGrade 2: Consider dose interruption until recovery to Grade ≤1 or baseline, then resume at same dose\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt dose until recovery to Grade ≤1 or baseline, then resume at next lower dose\u003c\/li\u003e\n\u003cli\u003eIf Grade 3 toxicity recurs, interrupt until recovery to Grade ≤1 or baseline, then resume elacestrant reduced by another dose level\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt dose until recovery to Grade ≤1 or baseline, then resume at next lower dose\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if Grade 4 or intolerable adverse reaction recurs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment recommended\u003c\/li\u003e\n\u003cli\u003eModerate (Child-Pugh B): Reduce dose to 258 mg qDay\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Avoid use; not studied\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955538987,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1017.jpg?v=1787022234"},{"product_id":"lucicapiva-capivasertib","title":"LuciCapiva (Capivasertib)","description":"\u003ch2\u003eAbout Capivasertib\u003c\/h2\u003e\u003cp\u003eCapivasertib is an orally bioavailable, small-molecule inhibitor of all three AKT isoforms. Capivasertib used in combination with fulvestrant , is indicated for adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with one or more PIK3CA\/AKT1\/PTEN-alterations,  following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within twelve months of completing adjuvant therapy.\u003csup id=\"cite_ref-Truqap_FDA_label_4-3\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003eBreast Cancer\u003c\/h3\u003e\u003cp\u003eIndicated in combination with fulvestrant for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer with ≥1 PIK3CA\/AKT1\/PTEN-alterations, following progression on at least 1 endocrine-based regimen in the metastatic setting; or recurrence during, or within 12 months after completing, adjuvant therapy\u003c\/p\u003e\u003ch4\u003eCapivasertib weekly dose schedule\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e400 mg PO BID (~12 hr apart) x 4 consecutive days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eRepeat weekly schedule until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eFulvestrant regimen during clinical trial\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e28-day cycles\u003c\/li\u003e\n\u003cli\u003eCycle 1: 500 mg IM on Days 1 and 15\u003c\/li\u003e\n\u003cli\u003eSubsequent cycles: 500 mg IM on Day 1\u003c\/li\u003e\n\u003cli\u003ePremenopausal and perimenopausal women: Administer a luteinizing hormone-releasing hormone (LHRH) agonist according to current clinical practice standards\u003c\/li\u003e\n\u003cli\u003eMen: Consider administering a LHRH agonist according to current clinical practice standards\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDose reductions for adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 320 mg BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 200 mg BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHyperglycemia\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eNote that recommendations are based on fasting glucose (FG) rather than random glucose\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eFG \u0026gt;ULN-160 mg\/dL (8.9 mmol\/L) or hemoglobin A1C (HbA1C) \u0026gt;7%\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eConsider initiation or intensification of oral antidiabetic treatment\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eFG 161-250 mg\/dL (9-13.9 mmol\/L)\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until FG decrease to ≤160 mg\/dL (≤8.9 mmol\/L)\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days, resume at same dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days, resume at 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eFG 251-500 mg\/dL (14-27.8 mmol\/L)\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until FG decrease to ≤160 mg\/dL (≤8.9 mmol\/L)\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days, resume at 1 lower dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days, permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eFG \u0026gt;500 mg\/dL (\u0026gt;27.8 mmol\/L) or life-threatening sequelae of hyperglycemia at any FG level\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eLife-threatening sequelae of hyperglycemia or if FG persists at ≥500 mg\/dL after 24 hr: Permanently discontinue\u003c\/li\u003e\n\u003cli\u003eIf FG ≤500 mg\/dL (or ≤27.8 mmol\/L) within 24 hr, follow above guidance for relevant grade\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eDiarrhea\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 2\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose or 1 lower dose as clinically indicated\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Resume at 1 lower dose\u003c\/li\u003e\n\u003cli\u003eFor recurrence: Reduce by 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose or 1 lower dose as clinically indicated\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCutaneous reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 2\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1 then resume at same dose\u003c\/li\u003e\n\u003cli\u003ePersistent or recurrent: Reduce by 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Resume at 1 lower dose\u003c\/li\u003e\n\u003cli\u003eFor recurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 2\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eResume at same dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until recovery to Grade ≤1\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in ≤28 days: Resume at same dose\u003c\/li\u003e\n\u003cli\u003eIf recovery occurs in \u0026gt;28 days: Resume at 1 lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eStrong and moderate CYP3A inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eStrong inhibitor: Avoid coadministration; if unavoidable, reduce dose to 320 mg BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eModerate inhibitor: Reduce dose to 320 mg PO BID x 4 days followed by 3 days off\u003c\/li\u003e\n\u003cli\u003eAfter discontinuing strong or moderate CYP3A inhibitor, resume capivasertib dosage (after 3-5 half-lives of CYP3A inhibitor) that was taken before initiating strong or moderate CYP3A inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl 30-89 mL\/min): No dosage adjustment required\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl 15-29 mL\/min): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (bilirubin ULN \u003cb\u003eor\u003c\/b\u003e bilirubin \u0026gt;1-1.5x ULN and any AST): No dosage adjustment required\u003c\/li\u003e\n\u003cli\u003eModerate (bilirubin \u0026gt;1.5-3x ULN and any AST): Monitor for adverse reactions due to potential increased capivasertib exposure\u003c\/li\u003e\n\u003cli\u003eSevere (bilirubin \u0026gt;3x ULN and any AST): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955571755,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1022.jpg?v=1787022236"},{"product_id":"lucifutib-futibatinib","title":"LuciFutib (Futibatinib)","description":"\u003ch2\u003eAbout Futibatinib\u003c\/h2\u003e\u003cp\u003eFutibatinib blocks a protein called FGFR, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor.\u003c\/p\u003e\u003ch3\u003eCholangiocarcinoma\u003c\/h3\u003e\u003cp\u003eIndicated for previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma in adults harboring fibroblast growth factor receptor 2 (\u003ci\u003eFGFR2\u003c\/i\u003e) gene fusions or other rearrangements\u003c\/p\u003e\u003cp\u003e20 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDose reductions for adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 16 mg qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 12 mg qDay\u003c\/li\u003e\n\u003cli\u003eUnable to tolerate 12 mg\/day: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRetinal pigment epithelial detachment (RPED)\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eContinue at current dose and continue periodic ophthalmic evaluation\u003c\/li\u003e\n\u003cli\u003eIf RPED resolves in ≤14 days, continue at current dose\u003c\/li\u003e\n\u003cli\u003eIf not resolving in ≤14 days, withhold; once resolved, resume at previous or lower dose\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHyperphosphatemia\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eSerum phosphate ≥5.5 to ≤7 mg\/dL: Continue at current dose and initiate phosphate-lowering therapy; monitor serum phosphate weekly\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eSerum phosphate \u0026gt;7 to ≤10 mg\/dL\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInitiate or adjust phosphate-lowering therapy; monitor serum phosphate weekly\u003c\/li\u003e\n\u003cli\u003eReduce dose to next level\u003c\/li\u003e\n\u003cli\u003eIf serum phosphate is ≤7 mg\/dL within 2 weeks after dose reduction, continue at this reduced dose\u003c\/li\u003e\n\u003cli\u003eIf serum phosphate is \u0026gt;7 mg\/dL within 2 weeks, further reduce dose to the next lower level\u003c\/li\u003e\n\u003cli\u003eIf serum phosphate is \u0026gt;7 mg\/dL within 2 weeks after second dose reduction, withhold until serum phosphate is ≤7 mg\/dL and resume at dose before suspending\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eSerum phosphate \u0026gt;10 mg\/dL\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInitiate or adjust phosphate lowering therapy and monitor serum phosphate weekly\u003c\/li\u003e\n\u003cli\u003eWithhold until phosphate is ≤7 mg\/dL and resume at next lower dose\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if serum phosphate is \u0026gt;7 mg\/dL within 2 weeks following 2 dose interruptions and reductions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold until toxicity resolves to Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume for hematologic toxicities resolving ≤1 week, at dose before suspending\u003c\/li\u003e\n\u003cli\u003eResume for other adverse reactions at next lower dose\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild to moderate (creatinine clearance [CrCl] 30-89 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl 15- 29 mL\/min), renal dialysis in end-stage renal disease (CrCl \u0026lt;15 mL\/min): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (total bilirubin ≤ULN and AST\u0026gt; ULN, or total bilirubin ≤1.5x ULN and any AST): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate or severe (total bilirubin \u0026gt;1.5x ULN and any AST): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955604523,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1072.jpg?v=1787022237"},{"product_id":"lucifilgo-filgotinib","title":"LuciFilgo (Filgotinib)","description":"\u003ch2\u003eAbout Filgotinib\u003c\/h2\u003e\u003cp\u003eFilgotinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have responded inadequately to, or who are intolerant to one or more disease‑modifying anti‑rheumatic drugs (DMARDs).Filgotinib may be used as monotherapy or in combination with methotrexate (MTX).\u003csup id=\"cite_ref-Jyseleca_EPAR_3-5\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3 id=\"section-how-is-it-taken\"\u003eHow is it taken?\u003c\/h3\u003e\u003cp\u003eFilgotinib is taken as a tablet once a day. Your doctor will advise on the dose for you. The tablets should be swallowed whole and taken with a glass of water, either with or without food. In some circumstances, your doctor may decide to alter the dose.\u003c\/p\u003e\u003cp\u003eTry to take your dose at the same time each day – if you’re late taking it, just take it as soon as you remember. If you miss your daily dose completely, carry on with the usual dose the next day – do not double it. If you take more than the recommended dose by mistake, contact your doctor straight away.\u003c\/p\u003e\u003cp\u003eBecause it’s a long-term treatment, it’s important to keep taking filgotinib (unless you have severe side effects):\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eeven if it doesn’t seem to be working at first\u003c\/li\u003e\n\u003cli\u003eeven when your symptoms improve (to help keep your condition under control).\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eYour doctor may decide to stop filgotinib and try another treatment if your symptoms haven’t improved very much after 6 months.\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955637291,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1162.jpg?v=1787022238"},{"product_id":"luciabro-abrocitinib","title":"LuciAbro (Abrocitinib)","description":"\u003ch2\u003eAbout Abrocitinib\u003c\/h2\u003e\u003cp\u003eAbrocitinib is a medication used for the treatment of atopic dermatitis (eczema).\u003csup id=\"cite_ref-Cibinqo_FDA_label_8-1\" class=\"reference\"\u003e\u003c\/sup\u003e It is a Janus kinase inhibitor .\u003c\/p\u003e\u003cp\u003eIn the EU, abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.\u003csup id=\"cite_ref-Cibinqo_EPAR_9-5\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003cp\u003eIn the US, abrocitinib is indicated for the treatment of people twelve years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.\u003csup id=\"cite_ref-Cibinqo_FDA_label_8-4\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003eAtopic Dermatitis\u003c\/h3\u003e\u003cp\u003eIndicated for refractory moderate-to-severe atopic dermatitis (AD) in patients aged ≥12 years whose disease is not adequately controlled with other systemic therapies, including biologics, or for whom those therapies are inadvisable\u003c\/p\u003e\u003cp\u003e100 mg PO qDay\u003c\/p\u003e\u003cp\u003eIf adequate response not achieved, consider increasing to 200 mg qDay\u003c\/p\u003e\u003cp\u003eDiscontinue if adequate response not achieved with 200 mg\/day\u003c\/p\u003e\u003cp\u003eUse lowest efficacious dose to maintain response\u003c\/p\u003e\u003cp\u003eUse with or without topical corticosteroids\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eCYP2C19 poor metabolizers or coadministration with strong CYP2C19 inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e50 mg qDay initially; if adequate response not achieved, may increase to 100 mg qDay\u003c\/li\u003e\n\u003cli\u003eDiscontinue if inadequate response after dosage increase\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eInfection\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIf serious or opportunistic infections develops, interrupt treatment until infection is controlled\u003c\/li\u003e\n\u003cli\u003eCarefully consider risks and benefits of treatment before reinitiating\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHematologic abnormalities\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003ePlatelet count \u0026lt;50,000\/mm\u003csup\u003e3\u003c\/sup\u003e: Discontinue therapy and monitor until platelet count \u0026gt;100,000\/mm\u003csup\u003e3\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003cli\u003eAbsolute lymphocyte count (ALC) \u0026lt;500 cells\/mm\u003csup\u003e3\u003c\/sup\u003e: Interrupt therapy; may restart once ALC \u0026gt;500 cells\/mm\u003csup\u003e3\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003cli\u003eAbsolute neutrophil count (ANC) \u0026lt;1000 cells\/mm\u003csup\u003e3\u003c\/sup\u003e: Interrupt therapy; may restart once ANC \u0026gt;1000 cells\/mm3\u003c\/li\u003e\n\u003cli\u003eHemoglobin (Hb) \u0026lt;8 g\/dL: Interrupt therapy; may restart once Hb \u0026gt;8 g\/dL\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (eGFR 60-89 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate (eGFR 30-59 mL\/min): 50 mg qDay initially; may double dose if adequate response not achieved\u003c\/li\u003e\n\u003cli\u003eSevere or end-stage renal disease (eGFR \u0026lt;29 mL\/min): Not recommended\u003c\/li\u003e\n\u003cli\u003ePatients on renal replacement therapy: Not studied; not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild or moderate (Child-Pugh A or B): No dose adjustment required\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955735595,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-119.jpg?v=1787022240"},{"product_id":"lucimomel-momelotinib","title":"LuciMomel (Momelotinib)","description":"\u003ch2\u003eAbout Momelotinib\u003c\/h2\u003e\u003cp\u003eONE PILL, ONCE DAILY\u003c\/p\u003e\u003cp\u003eMomelotinib is an anticancer medication used for the treatment of myelofibrosis.\u003csup id=\"cite_ref-Ojjaara_FDA_label_1-1\" class=\"reference\"\u003e\u003c\/sup\u003e It is a Janus kinase inhibitor and it is taken by mouth.\u003csup id=\"cite_ref-Ojjaara_FDA_label_1-2\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003cp\u003eOverall, momelotinib provides spleen, symptom, and anemia benefits to JAK inhibitor-naive patients with myelofibrosis regardless of baseline hemoglobin level, and greater anemia-related benefits vs. ruxolitinib in patients with hemoglobin \u0026lt;12 g\/dL\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955801131,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1131.jpg?v=1787022240"},{"product_id":"lucivalgan-valganciclovir","title":"LuciValgan (Valganciclovir)","description":"\u003ch2\u003eAbout Valganciclovir\u003c\/h2\u003e\u003cp\u003eValganciclovir is an antiviral medication used to treat cytomegalovirus (CMV) infection in those with HIV\/AIDS or following organ transplant (eg, heart, kidney, or kidney-pancreas transplant).\u003csup id=\"cite_ref-AHFS2016_3-0\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003cp\u003eIt is often used long term as it only suppresses rather than cures the infection.\u003c\/p\u003e\u003ch3\u003eCytomegalovirus Retinitis\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of CMV retinitis in patients with AIDS\u003c\/p\u003e\u003cp\u003eInduction dose: 900 mg PO q12hr for 21 days\u003c\/p\u003e\u003cp\u003eMaintenance dose: Following induction treatment, or in adults with inactive CMV retinitis, 900 mg PO qDay\u003c\/p\u003e\u003ch3\u003eCMV Colitis or Esophagitis in HIV-Infected Patients (Off-label)\u003c\/h3\u003e\u003cp\u003eTreat initially with ganciclovir 5 mg\/kg\/dose IV q12hr; once therapy is tolerated, change to valganciclovir 900 mg PO q12hr for 21-42 days or until signs and symptoms have resolved\u003c\/p\u003e\u003ch3\u003eCMV Prevention in Solid Organ Transplant\u003c\/h3\u003e\u003cp\u003eIndicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor CMV seropositive\/recipient CMV seronegative [D+\/R-])\u003c\/p\u003e\u003ch4\u003eKidney transplantation\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e900 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eBegin within 10 days of transplant until 200 days post-transplant\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eKidney-pancreas transplantation\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e900 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eBegin within 10 days of transplant until 100 days post-transplant\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHeart transplantation\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e900 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eBegin within 10 days of transplant until 100 days post-transplant\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003eHepatic impairment: Safety and efficacy not established\u003c\/p\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eCrCl 40-59 mL\/min: 450 mg PO q12hr (induction), THEN 450 mg qDay\u003c\/li\u003e\n\u003cli\u003eCrCl 25-39 mL\/min: 450 mg PO qDay (induction), THEN 450 mg q2days\u003c\/li\u003e\n\u003cli\u003eCrCl 10-24 mL\/min: 450 mg PO q2days (induction), THEN 450 mg 2 times\/week\u003c\/li\u003e\n\u003cli\u003e\u0026lt;10 mL\/min (on hemodialysis): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eAdults should use tablets, not oral solution\u003c\/p\u003e\u003ch3\u003eLymphoproliferative Disorder (Orphan)\u003c\/h3\u003e\u003cp\u003eOrphan designation for treatment of post-transplant lymphoproliferative disorder in combination with nanatinostat\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955866667,"sku":"RL3120241212s250","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1289.jpg?v=1787022243"},{"product_id":"lucires-resmetirom","title":"LuciRes (Resmetirom)","description":"\u003ch2\u003eAbout Resmetirom\u003c\/h2\u003e\u003cp\u003eResmetirom is a medication used for the treatment of noncirrhotic nonalcoholic steatohepatitis.\u003csup id=\"cite_ref-Rezdiffra_FDA_label_1-1\" class=\"reference\"\u003e\u003c\/sup\u003e It is a thyroid hormone receptor beta (NR1A2) agonist.\u003c\/p\u003e\u003ch3\u003eNonalcoholic Steatohepatitis\u003c\/h3\u003e\u003cp\u003eIndicated in conjunction with diet and exercise for treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)\u003c\/p\u003e\u003cp\u003eDosage is based on actual body weight\u003c\/p\u003e\u003cp\u003e\u0026lt;100 kg: 80 mg PO qDay\u003c\/p\u003e\u003cp\u003e≥100 kg: 100 mg PO qDay\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDosage modifications for CYP2C8 inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eStrong CYP2C8 inhibitors (eg, gemfibrozil): Not recommended\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eModerate CYP2C8 inhibitors (eg, clopidogrel)\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e\u0026lt;100 kg: Reduce to 60 mg PO qDay\u003c\/li\u003e\n\u003cli\u003e≥100 kg: Reduce to 80 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild or moderate (CrCl ≥30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate or severe (Child-Pugh B or C): May increase resmetirom plasma concentrations and risk of resmetirom adverse reactions\u003c\/li\u003e\n\u003cli\u003eDecompensated cirrhosis (consistent with moderate to severe hepatic impairment): Avoid use\u003c\/li\u003e\n\u003cli\u003eNASH cirrhosis: Safety and efficacy not established\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eLimitation of use: Avoid use in patients with decompensated cirrhosis\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955899435,"sku":"RL202501s250s300s380","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1267.jpg?v=1787022244"},{"product_id":"lucistir-stiripentol","title":"LuciStir (Stiripentol)","description":"\u003ch2\u003eAbout Stiripentol\u003c\/h2\u003e\u003cp\u003eStiripentol is an anticonvulsant medication used for the treatment of Dravet syndrome - a serious genetic brain disorder.\u003c\/p\u003e\u003cp\u003eIn the European Union, stiripentol is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in people with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.\u003c\/p\u003e\u003cp\u003eIn the United States, stiripentol is indicated for the treatment of seizures associated with Dravet syndrome in people two years of age and older taking clobazam.\u003csup id=\"cite_ref-Diacomit_FDA_label_4-1\" class=\"reference\"\u003e\u003c\/sup\u003e There are no clinical data to support the use of stiripentol as monotherapy in Dravet syndrome.\u003c\/p\u003e\u003cp\u003e\u003csup id=\"cite_ref-Diacomit_FDA_label_4-2\" class=\"reference\"\u003e\u003c\/sup\u003eIt is used in some countries as an add-on therapy with sodium valproate and clobazam for treating children with Dravet syndrome whose seizures are not adequately controlled. As of 2017, it was not known whether stiripentol remains useful as children become adolescents or adults.\u003c\/p\u003e\u003ch3\u003eSeizures\u003c\/h3\u003e\u003cp\u003eIndicated for seizures associated with Dravet syndrome in patients taking clobazam\u003c\/p\u003e\u003cp\u003eThere are no clinical data to support the use of stiripentol as monotherapy in Dravet syndrome\u003c\/p\u003e\u003cp\u003e50 mg\/kg\/day PO administered in 2 or 3 divided doses (ie, 16.67 mg\/kg TID or 25 mg\/kg BID); not to exceed 3000 mg\/day\u003c\/p\u003e\u003cp\u003eRound to the nearest possible dosage (usually within 50-150 mg of the recommended 50 mg\/kg\/day)\u003c\/p\u003e\u003cp\u003eIf the exact dosage is not achievable given the available strengths, a combination of the 2 strengths can be used to achieve this dosage\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eRenal and hepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eThere is no formal study of the pharmacokinetics and metabolism in patients with renal or hepatic impairment\u003c\/li\u003e\n\u003cli\u003eSince metabolites are eliminated mainly through the kidney and metabolized by the liver, administration to patients with moderate or severe renal or hepatic impairment is not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003ePrior to starting treatment, obtain a hematologic test\u003c\/p\u003e\u003ch4\u003eGradual withdrawal\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAs advised for most antiepileptic drugs (AEDs), if treatment is discontinued, gradually withdraw stiripentol to minimize the risk of increased seizure frequency and status epilepticus\u003c\/li\u003e\n\u003cli\u003eIn situations in which rapid withdrawal is medically required, appropriate monitoring is recommended\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955932203,"sku":"RL20250101s500","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1235.jpg?v=1787022245"},{"product_id":"luciapro-aprocitentan","title":"LuciApro (Aprocitentan)","description":"\u003ch2\u003eAbout Aprocitentan\u003c\/h2\u003e\u003cp\u003eAprocitentan is a once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan has a low potential for drug-drug interaction and a mechanism of action that is ideally suited for lowering blood pressure in adult patients whose hypertension is not adequately controlled by other drugs.\u003c\/p\u003e\u003ch3\u003eHypertension\u003c\/h3\u003e\u003cp\u003eIndicated for hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are not adequately controlled on other drugs\u003c\/p\u003e\u003cp\u003e12.5 mg PO qDay\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild to severe (eGFR ≥15 mL\/min): No dose adjustment required\u003c\/li\u003e\n\u003cli\u003eKidney failure (eGRF \u0026lt;15 mL\/min) or hemodialysis: Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh class A): No dose adjustment required\u003c\/li\u003e\n\u003cli\u003eModerate or severe (Child-Pugh class B or C): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003ch4\u003eBefore initiating and monitoring during treatment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eConfirm a negative pregnancy test in females of reproductive potential before initiating, monthly during treatment, and 1 month after discontinuing\u003c\/li\u003e\n\u003cli\u003eMeasure hemoglobin before initiating and periodically during treatment as clinically indicated\u003c\/li\u003e\n\u003cli\u003eMeasure serum aminotransferase levels and total bilirubin before initiating and periodically during treatment as clinically indicated\u003c\/li\u003e\n\u003cli\u003eMonitor for signs and symptoms of fluid retention, weight gain, and worsening heart failure\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955964971,"sku":"RL20250101s120","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1320.jpg?v=1787022246"},{"product_id":"lucifida-fidaxomicin","title":"LuciFida (Fidaxomicin)","description":"\u003ch2\u003eAbout Fidaxomicin\u003c\/h2\u003e\u003cp\u003eFidaxomicin is the first member of a class of narrow spectrum macrocyclic antibiotic drugs called tiacumicins. Fidaxomicin is minimally absorbed into the bloodstream when taken orally, is bactericidal, and selectively eradicates pathogenic \u003ci\u003eClostridioides difficile\u003c\/i\u003e with relatively little disruption to the multiple species of bacteria that make up the normal, healthy intestinal microbiota. The maintenance of normal physiological conditions in the colon may reduce the probability of recurrence of \u003ci\u003eClostridioides difficile\u003c\/i\u003e infection.\u003csup id=\"cite_ref-6\" class=\"reference\"\u003e\u003c\/sup\u003e\u003csup id=\"cite_ref-7\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch3\u003eClostridioides difficile-Associated Diarrhea\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of \u003ci\u003eClostridioides difficile\u003c\/i\u003e-associated diarrhea (CDAD)\u003c\/p\u003e\u003cp\u003e200 mg PO BID x10 days\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\u003cp\u003eDose adjustment not necessary\u003c\/p\u003e\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\u003cli\u003e\u003cp\u003eNot studied; dose adjustment not necessary since minimally absorbed\u003c\/p\u003e\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eTo reduce the development of drug-resistant bacteria and maintain the effectiveness, use only to treat infections that are proven or strongly suspected to be caused by \u003ci\u003eC difficile\u003c\/i\u003e\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797955997739,"sku":"RL20250101s600","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1310.jpg?v=1787022248"},{"product_id":"luciseta-sparsentan","title":"LuciSeta (Sparsentan)","description":"\u003ch2\u003eAbout Sparsentan\u003c\/h2\u003e\u003cp\u003eSparsentan is a medication used for the treatment of primary immunoglobulin A nephropathy.Sparsentan is an endothelin and angiotensin II receptor antagonist.\u003c\/p\u003e\u003ch3\u003eIgA Nephropathy\u003c\/h3\u003e\u003cp\u003eIndicated to slow kidney function decline in adults with primaryimmunoglobulin A nephropathy (IgAN) who are at risk for disease progression\u003c\/p\u003e\u003cp\u003e200 mg PO qDay initially; after 14 days, increase to recommended dose of 400 mg qDay, as tolerated\u003c\/p\u003e\u003cp\u003eWhen resuming treatment after an interruption, consider starting at 200 mg\/day, then after 14 days, increase to 400 mg\/day\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eALT\/AST \u0026gt;3x to ≤8x ULN\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eConfirm elevation with repeat measure\u003c\/li\u003e\n\u003cli\u003eIf confirmed, interrupt treatment, and monitor ALT\/AST levels and bilirubin at least weekly, and INR as needed, until levels return to pretreatment values and the patient is asymptomatic\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eDo not resume treatment if any of the following occurs without other cause found\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eALT\/AST \u0026gt;3x ULN and total bilirubin \u0026gt;2x ULN or INR \u0026gt;1.5\u003c\/li\u003e\n\u003cli\u003eALT\/AST \u0026gt;3x ULN, with symptoms of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and\/or eosinophilia (\u0026gt;5% eosinophils)\u003c\/li\u003e\n\u003cli\u003eALT\/AST \u0026gt;5x ULN for \u0026gt;2 weeks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003eIf treatment resumed, initiate at 200 mg qDay, with reassessment of hepatic enzyme levels and bilirubin within 3 days; close monitoring required in these patients\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eALT\/AST \u0026gt;8 x ULN\u003c\/h4\u003e\u003cul\u003e\u003cli\u003ePermanently discontinue if no other cause found\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eCoadministration of strong CYP3A4 inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eAvoid coadministration\u003c\/li\u003e\n\u003cli\u003eIf use is unavoidable, interrupt sparsentan\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (eGFR 30-89 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): No clinically significant differences in pharmacokinetics observed\u003c\/li\u003e\n\u003cli\u003eSevere (eGFR \u0026lt;30 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eMild, moderate, or severe (Child-Pugh A-C): Avoid use with any hepatic impairment because of risk of serious liver injury\u003c\/li\u003e\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797956063275,"sku":"RL20250101s1400","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1369.jpg?v=1787022249"},{"product_id":"lucifine-finerenone","title":"LUCIFINE (Finerenone)","description":"\u003ch2\u003eAbout Finerenone \u003c\/h2\u003e\u003cp\u003eFinerenone is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type\u003cspan class=\"nowrap\"\u003e \u003c\/span\u003e2 diabetes.\u003csup id=\"cite_ref-FDA_Kerendia_8-1\" class=\"reference\"\u003e\u003c\/sup\u003e Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA).\u003c\/p\u003e\u003ch3\u003eChronic Kidney Disease\u003c\/h3\u003e\u003cp\u003eIndicated to reduce risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease (CKD) associated with type 2 diabetes\u003c\/p\u003e\u003ch4\u003eStarting dose\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eDetermine starting dose by eGFR (mL\/min\/1.73m\u003csup\u003e2\u003c\/sup\u003e)\u003c\/li\u003e\n\u003cli\u003eeGFR ≥60: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eeGFR 25-60: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eeGFR \u0026lt;25: Not recommended\u003c\/li\u003e\n\u003cli\u003eIncrease dosage after 4 weeks to the target dose of 20 mg qDay based on eGFR and serum potassium thresholds\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDose adjustment\u003c\/h4\u003e\u003cp\u003eDose adjustment based on current serum potassium concentration (mEq\/L) and current dose\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eCurrently taking 10 mg qDay\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e≤4.8 mEq\/L: Increase dose to 20 mg qDay; if eGFR has decreased by more than 30% compared to previous measurement, maintain 10 mg dose\u003c\/li\u003e\n\u003cli\u003e\u0026gt;4.8-5.5 mEq\/L: Maintain 10 mg\/day\u003c\/li\u003e\n\u003cli\u003e\u0026gt;5.5 mEq\/L: Withhold dose; consider restarting at 10 mg qDay when potassium ≤5 mEq\/L\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eCurrently taking 20 mg qDay\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e≤4.8 mEq\/L: Maintain 20 mg qDay\u003c\/li\u003e\n\u003cli\u003e\u0026gt;4.8-5.5 mEq\/L: Maintain 20 mg\/day\u003c\/li\u003e\n\u003cli\u003e\u0026gt;5.5 mEq\/L: Withhold dose; restart at 10 mg qDay when potassium ≤5 mEq\/L\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eeGFR 15 to \u0026lt;90 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e: No clinically relevant differences in AUC or peak plasma concentration\u003c\/li\u003e\n\u003cli\u003eInitial dose and adjustments are based on eGFR and serum potassium levels\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild or moderate (Child-Pugh A or B): No dosage adjustment recommended\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Avoid\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797956096043,"sku":"RL20250101s50","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1367.jpg?v=1787022250"},{"product_id":"lucifezo-fezolinetant","title":"LuciFezo (Fezolinetant)","description":"\u003ch2\u003eAbout Fezolinetant\u003c\/h2\u003e\u003cp\u003eFezolinetant  is a medication used for the treatment of hot flashes (vasomotor symptoms) due to menopause.\u003csup id=\"cite_ref-Veozah_FDA_label_3-3\" class=\"reference\"\u003e\u003c\/sup\u003eIt is a small-molecule, orally active, selective neurokinin-3 (NK\u003csub\u003e3\u003c\/sub\u003e) receptor antagonist which is under development by for the treatment of sex hormone-related disorders.\u003c\/p\u003e\u003ch3\u003eMenopausal Vasomotor Symptoms\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of moderate-to-severe vasomotor symptoms (VMS) caused by menopause\u003c\/p\u003e\u003cp\u003e45 mg PO qDay\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild or moderate (eGFR 30-89 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e): No dose adjustment required\u003c\/li\u003e\n\u003cli\u003eSevere (eGFR 15-29 mL\/min\/1.73 m\u003csup\u003e2\u003c\/sup\u003e or end-stage renal disease [ESRD]): Contraindicated\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eAt baseline\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eALT or AST ≥2x ULN or if total bilirubin elevated (eg, ≥2x ULN): Do not start therapy\u003c\/li\u003e\n\u003cli\u003eMild or moderate (Child-Pugh A or B): Increased systemic exposure observed; no recommendations listed in prescribing information\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh C): Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eTreatment-related toxicity\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003e\u003cp\u003eALT\/AST \u0026gt;5x ULN OR ALT\/AST \u0026gt;3x ULN and total bilirubin \u0026gt;2x ULN: Discontinue\u003c\/p\u003e\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003ch4\u003eMonitoring\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eBefore initiating\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eObtain liver function tests (LFTs) including ALT\/AST, alkaline phosphatase, and total and direct bilirubin\u003c\/li\u003e\n\u003cli\u003eMay initiate if baseline hepatic transaminases \u0026lt;2x ULN and total bilirubin is normal\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eDuring treatment\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eMonitor LFTs monthly for the first 3 months, at 6 months, and 9 months after starting therapy\u003c\/li\u003e\n\u003cli\u003ePerform more frequent LFT monitoring (until resolution) if ALT\/AST \u0026gt;3x ULN occur\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797956128811,"sku":"RL20250101s200","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-133.jpg?v=1787022251"},{"product_id":"lucivora-vorasidenib","title":"LuciVora (Vorasidenib)","description":"\u003ch2\u003eAbout Vorasidenib\u003c\/h2\u003e\u003cp\u003eVorasidenib is an oral, brain-penetrant, dual inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) enzymes, approved for treating grade 2 IDH-mutant astrocytoma or oligodendroglioma in adults and children 12 years and older, following surgery. \u003c\/p\u003e\u003ch2\u003eAdult\u003c\/h2\u003e\u003ch3\u003eAstrocytoma or Oligodendroglioma\u003c\/h3\u003e\u003cp\u003eIndicated for Grade 2 astrocytoma or oligodendroglioma with susceptible isocitrate dehydrogenase (IDH)-1 or IDH-2 mutation following surgery including biopsy, sub-total resection, or gross total resection\u003c\/p\u003e\u003cp\u003e40 mg PO qDay until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eRecommended dosage reductions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst reduction: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond reduction: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if second dosage reduction not tolerated\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatotoxicity\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;ULN to 3 x ULN without concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eContinue current dose\u003c\/li\u003e\n\u003cli\u003eMonitor liver function tests (LFTs) weekly until recovery to\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;3-5 x ULN without concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at same dose for recovery ≤28 days or at reduced dose for recovery \u0026gt;28 days\u003c\/li\u003e\n\u003cli\u003eRecurrence: Hold therapy until recovery to ≤Grade 1 or baseline and resume at reduced dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;5-20 x ULN without concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold therapy until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose for recovery ≤28 days or permanently discontinue for recovery \u0026gt;28 days\u003c\/li\u003e\n\u003cli\u003eRecurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;3-20 x ULN with concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold therapy until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eRecurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eAny ALT or AST \u0026gt;20 x ULN\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold therapy until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eRecurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eCrCl \u0026gt;40 mL\/min: No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eCrCl ≤40 mL\/min or on dialysis: Not studied; monitor for adverse reactions and adjust dose as recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild or moderate (Child-Pugh class A or B): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh class C): Not studied; monitor for adverse reactions and adjust dose as recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eEvaluate blood chemistry and LFTs before initiating\u003c\/p\u003e\u003ch4\u003ePatient selection\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eTest for presence of IDH1 or IDH2 mutations in tumor specimens\u003c\/li\u003e\u003c\/ul\u003e\u003ch2\u003ePediatric\u003c\/h2\u003e\u003ch3\u003eAstrocytoma or Oligodendroglioma\u003c\/h3\u003e\u003cp\u003eIndicated for Grade 2 astrocytoma or oligodendroglioma with susceptible isocitrate dehydrogenase (IDH)-1 or IDH-2 mutation following surgery including biopsy, sub-total resection, or gross total resection in patients ≥12 years\u003c\/p\u003e\u003cp\u003e≥40 kg: 40 mg PO qDay\u003c\/p\u003e\u003cp\u003e\u0026lt;40 kg: 20 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eSafety and efficacy not established in patients \u0026lt;12 years\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eRecommended dosage adjustments\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e≥40 kg\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst reduction: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond reduction: 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u0026lt;40 kg\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst reduction: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if reduced dose not tolerated\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatotoxicity\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;ULN to 3 x ULN without concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eContinue current dose\u003c\/li\u003e\n\u003cli\u003eMonitor liver function tests (LFTs) weekly until recovery to\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;3-5 x ULN without concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at same dose for recovery ≤28 days or at reduced dose for recovery \u0026gt;28 days\u003c\/li\u003e\n\u003cli\u003eRecurrence: Hold therapy until recovery to ≤Grade 1 or baseline and resume at reduced dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;5-20 x ULN without concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold therapy until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose for recovery ≤28 days or permanently discontinue for recovery \u0026gt;28 days\u003c\/li\u003e\n\u003cli\u003eRecurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;3-20 x ULN with concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold therapy until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eRecurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eAny ALT or AST \u0026gt;20 x ULN\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold therapy until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eRecurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eCrCl \u0026gt;40 mL\/min: No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eCrCl ≤40 mL\/min or on dialysis: Not studied; monitor for adverse reactions and adjust dose as recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild or moderate (Child-Pugh class A or B): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh class C): Not studied; monitor for adverse reactions and adjust dose as recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eEvaluate blood chemistry and LFTs before initiating\u003c\/p\u003e\u003ch4\u003ePatient selection\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eTest for presence of IDH1 or IDH2 mutations in tumor specimens\u003c\/li\u003e\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797957603371,"sku":"RL3320250408","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-04-0564.jpg?v=1787022288"},{"product_id":"lucilazer-lazertinib","title":"LuciLazer (Lazertinib)","description":"\u003cp\u003eLazertinib is a potent irreversible, brain-penetrant, third-generation EGFR TKI exhibiting high selectivity for both activating and T790M \u003cem\u003eEGFR\u003c\/em\u003e resistance mutations while reducing the common drug-related treatment-emergent adverse events (TEAEs) (such as rash and diarrhea) associated with inhibition of wild-type (WT) \u003cem\u003eEGFR\u003c\/em\u003e activity .\u003c\/p\u003e\u003cp\u003eLazertinib comes as a tablet to take by mouth. It is usually taken with or without food once a day. Take lazertinib at around the same time every day. On the days that your receive amivantamab-vmjw injection, take lazertinib at any time before you receive the injection. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take lazertinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.\u003c\/p\u003e\u003cp\u003eSwallow the tablets whole; do not split, chew, or crush them.\u003c\/p\u003e\u003cp\u003eIf you vomit after taking lazertinib, do not take another dose. Continue your regular dosing schedule.\u003c\/p\u003e\u003cp\u003eYour doctor may need to temporarily or permanently stop your treatment or decrease your dose if you experience certain side effects. Be sure to talk to your doctor about how you are feeling during your treatment with lazertinib.\u003c\/p\u003e\u003cp\u003eThe length of your treatment depends on how well you respond to the medication and the side effects you experience. Continue to take lazertinib even if you feel well. Do not stop taking lazertinib without talking to your doctor.\u003c\/p\u003e\u003cp\u003eAsk your pharmacist or doctor for a copy of the manufacturer's information for the patient.\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797957636139,"sku":"RL3520250412","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-04-1151.jpg?v=1787022289"},{"product_id":"lucidela-idelalisib","title":"LuciDela (Idelalisib)","description":"\u003ch2\u003eAbout Idelalisib\u003c\/h2\u003e\u003cp\u003eIdelalisib  is a medication used to treat certain blood cancers. Idelalisib acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase.\u003c\/p\u003e\u003ch3\u003eChronic Lymphocytic Leukemia\u003c\/h3\u003e\u003cp\u003eIndicated, in combination with rituximab, for relapsed chronic lymphocytic leukemia (CLL) in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities\u003c\/p\u003e\u003cp\u003eStarting dose: 150 mg PO BID; continue treatment until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eFollicular B-cell Non-Hodgkin Lymphoma\u003c\/h3\u003e\u003cp\u003eJanuary 14, 2022: Indication for relapsed follicular B-cell non-Hodgkin lymphoma withdrawn\u003c\/p\u003e\u003cp\u003eUnable to enroll enough patients into a confirmatory trial required for the accelerated approval\u003c\/p\u003e\u003ch3\u003eSmall Lymphocytic Lymphoma\u003c\/h3\u003e\u003cp\u003eJanuary 14, 2022: Indication for small lymphocytic lymphoma withdrawn\u003c\/p\u003e\u003cp\u003eUnable to enroll enough patients into a confirmatory trial required for the accelerated approval\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003ePneumonitis: Discontinue with any severity of symptomatic pneumonitis\u003c\/p\u003e\u003cp\u003eCrCl ≥15 mL\/min: No dose adjustment required\u003c\/p\u003e\u003ch4\u003eALT\/AST\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\u0026gt;3-5 x ULN: Maintain dose; monitor at least weekly until ≤1 x ULN\u003c\/li\u003e\n\u003cli\u003e\u0026gt;5-20 x ULN: Withhold idelalisib; monitor ALT\/AST at least weekly until ≤1 x ULN, then resume at 100 mg BID\u003c\/li\u003e\n\u003cli\u003e\u0026gt;20 x ULN: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eBilirubin\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\u0026gt;1.5-3 x ULN: Maintain dose; monitor at least weekly until≤1 x ULN\u003c\/li\u003e\n\u003cli\u003e\u0026gt;3-10 x ULN: Withhold idelalisib; monitor bilirubin at least weekly until ≤1 x ULN, then resume at 100 mg BID\u003c\/li\u003e\n\u003cli\u003e\u0026gt;10 x ULN: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eDiarrhea\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eModerate: Maintain dose; monitor at least weekly until resolved\u003c\/li\u003e\n\u003cli\u003eSevere or hospitalization: Withhold idelalisib; monitor at least weekly until resolved, then resume dose at 100 mg BID\u003c\/li\u003e\n\u003cli\u003eLife-threatening: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eNeutropenia\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eANC 1 to \u0026lt;1.5 Gi\/L: Maintain dose\u003c\/li\u003e\n\u003cli\u003eANC 0.5 to \u0026lt;1 Gi\/L: Maintain dose; monitor ANC at least weekly\u003c\/li\u003e\n\u003cli\u003eANC \u0026lt;0.5 Gi\/L: Withhold idelalisib; monitor ANC at least weekly until ANC ≥0.5 Gi\/L, then resume at 100 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eThrombocytopenia\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003ePlatelets 50 to \u0026lt;75 Gi\/L: Maintain dose\u003c\/li\u003e\n\u003cli\u003ePlatelets 25 to \u0026lt;5 Gi\/L: Maintain dose; monitor platelets at least weekly\u003c\/li\u003e\n\u003cli\u003ePlatelets \u0026lt;25 Gi\/L: Withhold idelalisib; monitor platelets at least weekly until platelets ≥25 Gi\/L, then resume at 100 mg BID\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eInfections\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eEvidence of CMV infection or viremia\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt idelalisib in patients with evidence of active CMV infection of any grade or viremia (positive PCR or antigen test) until the viremia has resolved\u003c\/li\u003e\n\u003cli\u003eIf idelalisib is resumed, monitor patients by PCR or antigen test for CMV reactivation at least monthly\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade ≥3 sepsis or pneumonia\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eInterrupt idelalisib with until infection has resolved\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eEvidence of PJP infection\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eInterrupt idelalisib in patients with suspected PJP infection of any grade\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue idelalisib if PJP infection is confirmed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eOther severe or life-threatening toxicities\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eWithhold drug until toxicity is resolved\u003c\/li\u003e\n\u003cli\u003eIf resuming treatment after interruption for other severe or life-threatening toxicities, reduce dose to 100 mg twice daily\u003c\/li\u003e\n\u003cli\u003eDiscontinue idelalisib permanently for recurrence of other severe or life-threatening idelalisib-related toxicity upon rechallenge\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eMonitoring\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eMonitor blood counts at least q2 weeks for first 6 months, and at least weekly if neutrophil counts \u0026lt;1x 10\u003csup\u003e9\u003c\/sup\u003e\/L\u003c\/li\u003e\n\u003cli\u003eMonitor ALT and AST q2 weeks for first 3 months, q4 weeks for next 3 months, then q1-3 months thereafter\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797957701675,"sku":"RL3520250416","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-04-1335.jpg?v=1787022291"},{"product_id":"lucicob-cobimetinib","title":"LuciCob (Cobimetinib)","description":"\u003ch2\u003eAbout Cobimetinib \u003c\/h2\u003e\u003cp\u003eCobimetinib is a MEK inhibitor. Cobimetinib is an anti-cancer medication used to treat melanoma and histiocytic neoplasms. \u003c\/p\u003e\u003ch3\u003eMelanoma\u003c\/h3\u003e\u003cp\u003eIndicated for unresectable or metastatic melanoma in patients with a BRAF V600E or V600K mutation, in combination with vemurafenib\u003c\/p\u003e\u003cp\u003e60 mg PO qDay for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eVemurafenib: 960 mg PO BID on days 1-28 of an every 28-day cycle\u003c\/p\u003e\u003ch3\u003eHistiocytic Neoplasms\u003c\/h3\u003e\u003cp\u003eIndicated as a single agent for adults with histiocytic neoplasms\u003c\/p\u003e\u003cp\u003e60 mg PO qDay for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003eNew primary malignancies (cutaneous and noncutaneous): No dosage modification required\u003c\/p\u003e\u003cp\u003eAvoid concurrent use of cobimetinib and strong or moderate CYP3A inducers including but not limited to carbamazepine, efavirenz, phenytoin, rifampin, and St. John’s Wort\u003c\/p\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eMild-to-severe (Child-Pugh A to C): No dosage adjustment necessary\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl 30-89 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Safety and efficacy not established\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCoadministration with CYP3A inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eDo not take strong or moderate CYP3A inhibitors while taking cobimetinib\u003c\/li\u003e\n\u003cli\u003eIf concurrent short-term (≤14 days) use of moderate CYP3A inhibitors is unavoidable for patients taking cobimetinib 60 mg, reduce dose to 20 mg; after the moderate CYP3A inhibitor is discontinued, resume previous cobimetinib dose\u003c\/li\u003e\n\u003cli\u003eUse an alternative to a strong or moderate CYP3A inhibitor in patients who are taking a reduced dose of cobimetinib (40 or 20 mg daily)\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eDose reductions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 40 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSubsequent modification: Permanently discontinue cobimetinib if unable to tolerate 20-mg dose\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHemorrhage\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold cobimetinib for up to 4 wk; if improved to grade 0 or 1, resume at the next lower dose level; permanently discontinue if not improved within 4 wk\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCardiomyopathy\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eAsymptomatic\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eDefinition: Absolute decrease in LVEF from baseline of \u0026gt;10% and less than institutional lower limit of normal (LLN) Withhold cobimetinib for 2 wk; repeat LVEF\u003c\/li\u003e\n\u003cli\u003eResume at next lower dose if all of the following are present: LVEF is ≥LLN and absolute decrease from baseline LVEF is ≤10%\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if any of the following are present: LVEF is 10%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eSymptomatic LVEF decrease from baseline\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold cobimetinib for 4 wk; repeat LVEF\u003c\/li\u003e\n\u003cli\u003eResume at next lower dose if all of the following are present:\u003c\/li\u003e\n\u003cli\u003eSymptoms resolve and LVEF is ≥LLN and absolute decrease from baseline LVEF is ≤10%\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if any of the following are present:\u003c\/li\u003e\n\u003cli\u003eSymptoms persist, or LVEF is 10%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eDermatologic reactions\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 2 (intolerable) or grades 3 or 4: Withhold or reduce dose\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eRetinopathy or retinal vein occlusion\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eSerous retinopathy: Withhold for up to 4 wk; if signs and symptoms improve, resume at the next lower dose level; permanently discontinue if not improved or symptoms recur at the lower dose within 4 wk\u003c\/li\u003e\n\u003cli\u003eRetinal vein occlusion: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatoxicity\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst occurrence grade 4: Withhold for up to 4 wk; if improved to grade 0 or 1, resume at the next lower dose level; permanently discontinue if not improved within 4 wk\u003c\/li\u003e\n\u003cli\u003eRecurrent grade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRhabdomyolysis and elevated CPK\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 4 creatine phosphokinae (CPK) elevation or any CPK elevation plus myalgia: Withhold for up to 4 wk; if improved to ≤grade 3, resume at the next lower dose level; permanently discontinue if not improved within 4 wk\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003ePhotosensitivity\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 2 (intolerable), grades 3 or 4: Withhold for up to 4 wk; if improved to grade 0 or 1, resume at the next lower dose level; permanently discontinue if not improved within 4 wk\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eOther adverse events\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 2 (intolerable) adverse reactions or any grade 3\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eWithhold for up to 4 wk; if improved to grade 0 or 1, resume at the next lower dose level; permanently discontinue if not improved within 4 wk\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eFirst occurrence of any grade 4 adverse reaction\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until adverse reaction improves to grade 0 or 1 and then resume at the next lower dose level, OR\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eRecurrent grade 4 adverse reaction\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797957832747,"sku":"RL3520250416","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-04-1325.jpg?v=1787022292"},{"product_id":"lucivande-vandetanib","title":"LuciVande 100 (Vandetanib)","description":"\u003cp\u003e\u003cstrong\u003eAbout Vandetanib \u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.\u003c\/p\u003e\u003ch3\u003eMedullary Thyroid Cancer\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease\u003c\/p\u003e\u003cp\u003e300 mg PO qDay with or without food\u003c\/p\u003e\u003cp\u003eContinued until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eDose Reduction\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade ≥3 toxicities: Reduce to 200 mg qDay; then further reduce to 100 mg qDay if necessary\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eInterrupt therapy\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eCorrected QT interval, Fridericia (QTcB) interval \u0026gt;500 msec: Resume at reduce dose once QTcF ≤450 msec\u003c\/li\u003e\n\u003cli\u003eGrade ≥3 toxicity: Resume at reduced dose once toxicity resolves to Grade \u0026lt;1\u003c\/li\u003e\n\u003cli\u003eRecurrent toxicities: Reduce dose to 100 mg once toxicity resolves to Grade \u0026lt;1, if continued treatment is warranted\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eCrCl ≥50 mL\/min: No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate (CrCl 30 to \u0026lt;50 mL\/min): Reduce starting dose to 200 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Not recommended\u003c\/li\u003e\n\u003cli\u003eEnd-stage renal disease requiring dialysis: Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child Pugh A): Dose adjustment not described in manufacturer's label\u003c\/li\u003e\n\u003cli\u003eModerate-to-severe (Child-Pugh B or C): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797957996587,"sku":"RL362025060601","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-06-0674.jpg?v=1787022294"},{"product_id":"lucivande-300-vandetanib","title":"LuciVande 300 (Vandetanib)","description":"\u003cp\u003e\u003cstrong\u003eAbout Vandetanib \u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eVandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Medullary_Thyroid_Cancer\"\u003eMedullary Thyroid Cancer\u003c\/span\u003e\u003c\/h3\u003e\u003cp\u003eIndicated for treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease\u003c\/p\u003e\u003cp\u003e300 mg PO qDay with or without food\u003c\/p\u003e\u003cp\u003eContinued until disease progression or unacceptable toxicity occurs\u003c\/p\u003e\u003ch3\u003e\u003cspan id=\"Dosage_Modifications\"\u003eDosage Modifications\u003c\/span\u003e\u003c\/h3\u003e\u003ch4\u003e\u003cspan id=\"Dose_Reduction\"\u003eDose Reduction\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade ≥3 toxicities: Reduce to 200 mg qDay; then further reduce to 100 mg qDay if necessary\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u003cspan id=\"Interrupt_therapy\"\u003eInterrupt therapy\u003c\/span\u003e\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eCorrected QT interval, Fridericia (QTcB) interval \u0026gt;500 msec: Resume at reduce dose once QTcF ≤450 msec\u003c\/li\u003e\n\u003cli\u003eGrade ≥3 toxicity: Resume at reduced dose once toxicity resolves to Grade \u0026lt;1\u003c\/li\u003e\n\u003cli\u003eRecurrent toxicities: Reduce dose to 100 mg once toxicity resolves to Grade \u0026lt;1, if continued treatment is warranted\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Renal_impairment\"\u003eRenal impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eCrCl ≥50 mL\/min: No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eModerate (CrCl 30 to \u0026lt;50 mL\/min): Reduce starting dose to 200 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Not recommended\u003c\/li\u003e\n\u003cli\u003eEnd-stage renal disease requiring dialysis: Not studied\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003e\u003cspan id=\"Hepatic_impairment\"\u003eHepatic impairment\u003c\/span\u003e\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child Pugh A): Dose adjustment not described in manufacturer's label\u003c\/li\u003e\n\u003cli\u003eModerate-to-severe (Child-Pugh B or C): Not recommended\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797958029355,"sku":"RL362025060602","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-06-0687.jpg?v=1787022295"},{"product_id":"lucilenacap-lenacapavir","title":"LuciLenacap (Lenacapavir)","description":"\u003cp\u003e\u003cstrong\u003eAbout Lenacapavir\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eLenacapavir is a prescription medicine approved by the FDA for the treatment of HIV in adults for whom other HIV medicines have not worked and who meet certain requirements, as determined by a health care provider. Lenacapavir is always used in combination with other HIV medicines.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eAdults\u003c\/strong\u003e\u003c\/p\u003e\u003cp\u003eAt first, 600 milligrams (mg) (2 tablets) once a day on Days 1 and 2.\u003c\/p\u003e\u003cp\u003eFollowed by 300 mg (1 tablet) once on Day 8. Then, 927 mg (2 vials) injected under the skin on Day 15. For maintenance, 927 mg (2 vials) injected under the skin once a day every 6 months (26 weeks).\u003c\/p\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797958094891,"sku":"RL362025060603","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-06-0684.jpg?v=1787022297"}],"url":"https:\/\/xomeds.com\/collections\/lucius-pharmaceuticals.oembed","provider":"XOMEDS","version":"1.0","type":"link"}